Las Vegas, NV -- (SBWIRE) -- 01/14/2013 -- MANHATTAN PHARMS INC (OTC:TGTX) is a clinical-stage biopharmaceutical company, focused on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs.
The stock has been making an explosive move up in recent weeks from well under $2 in December to recent highs over $5 per share. Currently trading just over $4 TGTX is moving on big news from the Company.
TG Therapeutics has the worldwide rights to commercialize ublituximab for all indications, including the treatment of cancer and autoimmune diseases, such as non-hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL).
In January, TGTX announced that the U.S. Food and Drug Administration ("FDA") has cleared its Investigational New Drug Application for TGR-1202, the Company's novel, highly specific PI3K-Delta inhibitor being developed jointly with Rhizen Pharmaceuticals, S A.
OTCMAGIC has recently published a new article on TG Therapeutics that goes more into detail on what is really happening. To find out what OTCMAGIC projects for TGTX both short term and long term please visit our article here: TGTX
OTCMAGIC is the fastest growing, most exciting Penny Stocks Newsletter on the Internet. Visit OTCMAGIC today and find out why 30,000 investors visit every month. If you love finding out the inside scoop on today’s hottest Penny Stock Winners than you will love OTCMAGIC.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PLEASE NOTE: OTCMagic.com employees are not registered as an Investment Advisor in any jurisdiction whatsoever. Full disclaimer can be read at otcmagic/disclaimer. Release of Liability: Through use of this website viewing or using you agree to hold OTCMagic.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss monetary or otherwise, damage monetary or otherwise, or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. OTCMagic.com affiliates may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. OTCMagic.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and OTCMagic.com. We make no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. This is not a solicitation to buy or sell any securities. Any claims or Statements should be deemed hypothetical. OTCMagic.com, nor any of its affiliates are not registered investment advisors or broker dealers.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)